鼻腔NK/T细胞淋巴瘤的疗效及预后分析  

Prognostic Factors and Curative Efficacy of Nasal NK/T-cell Lymphoma

作　　者：罗杨坤[1] 谭燕[1] 付彬玉[1] 文浩[1] 

机构地区：[1]四川省肿瘤医院放射治疗中心,四川成都610041

出　　处：《中国现代医生》2010年第4期6-7,21,共3页China Modern Doctor

摘　　要：目的分析鼻腔NK/T细胞淋巴瘤的疗效及预后因素。方法分析1996年9月～2005年9月本院收治的60例Ⅰ/Ⅱ期鼻腔NK/T细胞淋巴瘤资料。单因素分析采用Kaplan-Meier法,多因素分析运用Cox比例风险模型。结果全组5年总生存率(OS)和无病生存率(DFS)分别为56.4%与38.6%。达CR与未达CR的5年OS率分别为60.4%及16.0%(P<0.05)。单纯化疗与综合治疗相比,5年OS率分别为18.8%及56.7%(P<0.05),5年DFS分别为15.2%和51.4%。单纯放疗与综合治疗相比,5年OS率为60.2%及56.7%(P>0.05),5年DFS分别为57.0%及51.4%(P>0.05)。放疗后化疗和化疗后放疗的5年OS率及DFS率分别为59.2%及52.6%,和53.6%及47.5%,无统计学意义。多因素分析显示,B症状、CR率、超腔为独立预后因素。结论单纯化疗在早期鼻腔NK/T细胞淋巴瘤疗效差。B症状,超腔,CR率是判断预后的指标。Objective To analyze the curative efficacy and prognostic factors in 60 cases of primary nasal NK/T-cell lymphoma. Methods From Sept.1996 to Sept.2005, 60 eases of nasal NK/T-cell lymphoma were diagnosed pathologically. Data from these patients were reviewed. Kaplan-Meier methods were applied in single-factor analysis,and the Cox regression model was applied in multivariate analysis. Results The 5-year overall survival（OS）rate and disease free survival（DFS）rate for all patients were 56.4% and 38.6%. The 5-year OS rate for CR and no-CR patients was 60.4% and 16.0%（P〈0.05）. The 5-year OS rate and DFS rate of chemotherapy alone group and combined therapy group were 18.8% and 15.2%,56.7% and 51.4%,respectively. The 5-year OS rate and DFS rate were 59.2% and 52.6% for radiotherapy followed by chemotherapy,and 53.6% and 47.5% for chemotherapy followed by radiotherapy. The COX regression showed that B symptoms,local tumor invasion out of the nasal cavity and CR rate were independent prognostic factors. Conclusion NK/T-cell lymphoma shows low chemotherapy sensitivity. B symptoms,local tumor invasion out of the nasal cavity and CR rate are independent prognostic factors.

关 键 词：NK/T细胞淋巴瘤 放射治疗 化学治疗 预后 

分 类 号：R739.62[医药卫生—肿瘤]